Table 2.

Antithrombotic therapies and vascular events in COVID-19 patients and with SARS-CoV-2 negative pneumonia.

	COVID-19 (N = 127)	SARS-CoV-2 negative Pneumonia (N = 24)	p
Antithrombotic therapy
None, %	22.0% (N = 28)	45.8% (N = 11)	0.015
Prophylactic LMWH, %	65.4% (N = 83)	54.2% (N = 13)	0.296
Intermediate/treatment dose LMWH, %	12.6% (N = 16)	0%	0.076
Thrombotic events, % (95%CI)
Overall	5.5% (2.2–11.0%) (N = 7)	0% (0–14.2%)	0.004*
ICU	15.2% (5.1–35.9%) (N = 5)
Non-ICU	2.1% (0.3% -7.5%) (N = 2)
Bleeding events, % (95%CI)
Overall	3.8% (1.2–8.6%) (N = 5)	0% (0–14.2%)	0.448*
ICU	6.1% (0.7–20.2%) (N = 2)
Non-ICU	3.2% (0.7–9.0%) (N = 3)

Bold values denote statistical significance at the p < 0.05 level.

ICU intensive care unit, LMWH low molecular weight heparin.

*p value of 0.013 for thrombotic events in ICU vs. non-ICU COVID-19 patients, and p value of 0.604 for bleeding events in ICU vs. non-ICU COVID-19 patients.